

DAFTAR PUSTAKA

- Akbari, M., Shomali, N., Faraji, A., Shanehbandi, D., Asadi, M., Mokhtarzadeh, A., Shabani, A., & Baradaran, B. (2019). CD133: An emerging prognostic factor and therapeutic target in colorectal cancer. *Cell Biology International*, 44(2), 368–380. <https://doi.org/10.1002/cbin.11243>
- Amaya Padilla, M. A., Binju, M., Wan, G., Rahmanto, Y. S., Kaur, P., & Yu, Y. (2019). Relationship between ovarian cancer stem cells, epithelial mesenchymal transition and tumour recurrence. *Cancer Drug Resistance*, 1127–1135. <https://doi.org/10.20517/cdr.2019.76>
- Auersperg, N. (2013). The Stem-Cell Profile of Ovarian Surface Epithelium is Reproduced in the Oviductal Fimbriae , with Increased Stem-Cell Marker Density in Distal Parts of the Fimbriae. *International Journal of Gynecological Pathology*, 32, 444–453. <https://doi.org/10.1097/PGP.0b013e3182800ad5>
- Baba, T., Convery, P. A., Matsumura, N., Whitaker, R. S., Kondoh, E., Perry, T., Huang, Z., Bentley, R. C., Mori, S., Fujii, S., Marks, J. R., Berchuck, A., & Murphy, S. K. (2009). Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. *Oncogene*, 28(2), 209–218. <https://doi.org/10.1038/onc.2008.374>
- Bapat, S. A., Koppikar, C. B., & Kurrey, N. K. (2005). Stem and Progenitor-Like Cells Contribute to the Aggressive Behavior of Human Epithelial Ovarian Cancer. *Cancer Research*, 65(8), 3025–3030.
- Barzegar Behrooz, A., Syahir, A., & Ahmad, S. (2019). CD133: beyond a cancer stem cell biomarker. *Journal of Drug Targeting*, 27(3), 257–269. <https://doi.org/10.1080/1061186X.2018.1479756>
- Beral, V., Gaitskell, K., Hermon, C., Moser, K., Reeves, G., & Peto, R. (2015). Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. *Lancet (London, England)*, 385(9980), 1835–1842. [https://doi.org/10.1016/S0140-6736\(14\)61687-1](https://doi.org/10.1016/S0140-6736(14)61687-1)
- Brossa, A., Papadimitriou, E., Collino, F., Incarnato, D., Oliviero, S., Camussi, G., & Bussolati, B. (2018). Role of CD133 Molecule in Wnt Response and Renal Repair. In *STEM CELLS Translational Medicine* (Vol. 7, Issue 3, pp. 283–294). Wiley. <https://doi.org/10.1002/sctm.17-0158>
- Budiana, I. N. G., Angelina, M., & Pemayun, T. G. A. (2019). Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *Journal of the Turkish-German Gynecological Association*, 20(1), 47–54. <https://doi.org/10.4274/jtgga.galenos.2018.2018.0119>
- Burges, A., & Schmalfeldt, B. (2011). Diagnosis and Treatment. *Deutsches Arzteblatt International*, 108(38), 635–641. <https://doi.org/10.3238/arztebl.2011.0635>
- Charan, J., & Biswas, T. (2013). How to calculate sample size for different study designs in medical research? *Indian Journal of Psychological Medicine*, 35(2), 121–126. <https://doi.org/10.4103/0253-7176.116232>
- Chen, W. C., Qiu, J. T., Lai, C. H., Huang, H. J., Lin, C. T., Chen, M. Y., Chou, H. H., Huang, K. G., & Chang, T. C. (2017). Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan. *PLoS ONE*, 12(5), 1–14. <https://doi.org/10.1371/journal.pone.0175703>
- Cioce, M., & Ciliberto, G. (2012). On the connections between cancer stem cells

- and EMT. *Cell Cycle*, 11(23), 4301. <https://doi.org/10.4161/cc.22809>
- Clevers, H. (2011). The cancer stem cell : premises , promises and challenges. *Nature Medicine*, 17(3), 313–319. <https://doi.org/10.1038/nm.2304>
- Curley, M. D., Therrien, V. A., Cummings, C. L., Sergent, P. A., Koulouris, C. R., Friel, A. M., Roberts, D. J., Seiden, M. V., Scadden, D. T., Rueda, B. O. R., & Foster, R. (2009). CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. *Stem Cells*, 27(12), 2875–2883. <https://doi.org/10.1002/stem.236>
- Erickson, B. K., Conner, M. G., & Jr, C. N. L. (2013). The role of the fallopian tube in the origin of ovarian cancer. *The American Journal of Obstetrics & Gynecology*, 209(5), 409–414. <https://doi.org/10.1016/j.ajog.2013.04.019>
- Ferrandina, G., Martinelli, E., Petrillo, M., Prisco, M. G., Zannoni, G., Sioletic, S., & Scambia, G. (2009). CD133 antigen expression in ovarian cancer. *BMC Cancer*, 9, 221. <https://doi.org/10.1186/1471-2407-9-221>
- Globocan. (2018). *Ovarian Cancer - The Global Cancer Observatory*.
- Gross, A. L., Kurman, R. J., Vang, R., Shih, I., & Visvanathan, K. (2010). Precursor Lesions of High-Grade Serous Ovarian Carcinoma : Morphological and Molecular Characteristics. *Journal of Oncology*, 2010. <https://doi.org/10.1155/2010/126295>
- Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009). Cancer stem cells : mirage or reality ? *Nature Medicine*, 15(9), 1010–1012. <https://doi.org/10.1038/nm0909-1010>
- Hanahan, & Weinberg. (2000). The Hallmarks of cancer. *Cell*, 100, 57–70.
- Hashimoto, O., Shimizu, K., Semba, S., Chiba, S., Ku, Y., Yokozaki, H., & Hori, Y. (2011). Hypoxia Induces Tumor Aggressiveness and the Expansion of CD133-Positive Cells in a Hypoxia-Inducible Factor-1 alpha-Dependent Manner in Pancreatic Cancer Cells. *Pathobiology*, 78, 181–192. <https://doi.org/10.1159/000325538>
- Hatano, Y., Hatano, K., & Tamada, M. (2019). A Comprehensive Review of Ovarian Serous Carcinoma. *Advances In Anatomic Pathology*, 26(5), 329–339.
- Hay, E. D. (2005). The Mesenchymal Cell , Its Role in the Embryo , and the Remarkable Signaling Mechanisms That Create It. *Developmental Dynamics*, 233(May), 706–720. <https://doi.org/10.1002/dvdy.20345>
- Imperiali, B., & O'Connor, S. E. (1999). Effect of N-linked glycosylation on glycopeptide and glycoprotein structure. *Current Opinion in Chemical Biology*, 3(6), 643–649. [https://doi.org/10.1016/S1367-5931\(99\)00021-6](https://doi.org/10.1016/S1367-5931(99)00021-6)
- Jang, G.-B., Kim, J.-Y., Cho, S.-D., Park, K.-S., Jung, J.-Y., Lee, H.-Y., Hong, I.-S., & Nam, J.-S. (2015). Blockade of Wnt/ β -catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. *Scientific Reports*, 5(1), 12465. <https://doi.org/10.1038/srep12465>
- Jang, J.-W., Song, Y., Kim, S.-H., Kim, J.-S., Kim, K. M., Choi, E. K., Kim, J., & Seo, H. R. (2017). CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma. *Cancer Letters*, 389, 1–10. <https://doi.org/10.1016/j.canlet.2016.12.023>
- Jeng, K.-S., Sheen, I.-S., Jeng, W.-J., Yu, M.-C., Hsiau, H.-I., Chang, F.-Y., & Tsai, H.-H. (2013). Activation of the sonic hedgehog signaling pathway occurs in the CD133 positive cells of mouse liver cancer Hepa 1-6 cells. *OncoTargets and Therapy*, 6, 1047–1055. <https://doi.org/10.2147/OTT.S44828>

- Jiang, H., Lin, X., Liu, Y., Gong, W., Yu, Y., Xie, Y., Sun, X., Feng, Y., Janzen, V., & Chen, T. (2012). Transformation of Epithelial Ovarian Cancer Stemlike Cells into Mesenchymal Lineage via EMT Results in Cellular Heterogeneity and Supports Tumor Engraftment. *Molecular Medicine*, *18*, 1197–1208. <https://doi.org/10.2119/molmed.2012.00075>
- Kazama, S., Kishikawa, J., Kiyomatsu, T., Kawai, K., Nozawa, H., & Ishihara, S. (2018). Expression of the stem cell marker CD133 is related to tumor development in colorectal carcinogenesis. *Asian Journal of Surgery*, *41*(3), 274–278. <https://doi.org/10.1016/j.asjsur.2016.12.002>
- Keymoosi, H., Gheytauchi, E., Asgari, M., Shariftabrizi, A., & Madjd, Z. (2014). ALDH1 in Combination with CD44 as Putative Cancer Stem Cell Markers are Correlated with Poor Prognosis in Urothelial Carcinoma of the Urinary Bladder. *Asian Pacific Journal of Cancer Prevention*, *15*, 2013–2020.
- Kitamura, H., Okudela, K., Yazawa, T., Sato, H., & Shimoyamada, H. (2009). Lung Cancer Cancer stem cell : Implications in cancer biology and therapy with special reference to lung cancer. *Lung Cancer*, *66*, 275–281. <https://doi.org/10.1016/j.lungcan.2009.07.019>
- Klapdor, R., Wang, S., Hacker, U., Büning, H., Morgan, M., Dörk, T., Hillemanns, P., & Schambach, A. (2017). Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy. *Human Gene Therapy*, *28*(10), 886–896. <https://doi.org/10.1089/hum.2017.168>
- Konishi, H., Asano, N., Imatani, A., Kimura, O., Kondo, Y., Jin, X., Kanno, T., Hatta, W., Ara, N., Asanuma, K., Koike, T., & Shimosegawa, T. (2016). Notch1 directly induced CD133 expression in human diffuse type gastric cancers. *Oncotarget*, *7*(35), 56598–56607. <https://doi.org/10.18632/oncotarget.10967>
- Kumar, D., Kumar, S., Gorain, M., Tomar, D., Patil, H. S., & ... (2016). Notch1-MAPK signaling axis regulates CD133+ cancer stem cell-mediated melanoma growth and angiogenesis. In *Journal of Investigative ...* Elsevier. <https://www.sciencedirect.com/science/article/pii/S0022202X16322321>
- Kumar, V., Abbas, A. K., & Aster, J. C. (2018). The Cell as a Unit of Health and Disease. In *Robbins Basic Pathology* (10th editi, pp. 25–27).
- Kurman, R., Carcangiu, M., Herrington, C., & Young, R. (2014). *WHO classification of tumours of female reproductive organs* (4th ed). International Agency for Research on Cancer.
- Kurman, R. J., & Shih, I. (2016). The Dualistic Model of Ovarian Carcinogenesis Revisited , Revised , and Expanded. *The American Journal of Pathology*, *186*(4), 733–747. <https://doi.org/10.1016/j.ajpath.2015.11.011>
- Kurman, R. J., & Shih, L.-M. (2008). Pathogenesis of Ovarian Cancer: Lesson from Morphology and Molecular Biology and their Clinical Implications. *Int J Gynecol Pathol*, *27*(2), 151–160. <https://doi.org/10.1097/PGP.0b013e318161e4f5>.Pathogenesis
- Kurman, R. J., & Shih, L.-M. (2010). The Origin and Pathogenesis of Epithelial Ovarian Cancer - a Proposed Unifying Theory. *Am J Surg Pathol*, *34*(3), 433–443. <https://doi.org/10.1097/PAS.0b013e3181cf3d79>.The
- Latifi, A., Abubaker, K., Castrechini, N., Ward, A. C., Liongue, C., Dobill, F., Kumar, J., Thompson, E. W., Quinn, M. A., Findlay, J. K., & Ahmed, N. (2011). Cisplatin Treatment of Primary and Metastatic Epithelial Ovarian Carcinomas Generates Residual Cells With Mesenchymal Stem Cell-Like

- Profile. *Journal of Cellular Biochemistry*, 112(May), 2850–2864.
<https://doi.org/10.1002/jcb.23199>
- Lee, Y., Miron, A., Drapkin, R., Nucci, M. R., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R. W., Cramer, D. W., McKeon, F. D., & Crum, C. P. (2007). A candidate precursor to serous carcinoma that originates in the distal fallopian tube. *The Journal of Pathology*, 211(1), 26–35. <https://doi.org/10.1002/path.2091>
- Lengyel, E. (2010). Ovarian Cancer Development and Metastasis. *The American Journal of Pathology*, 177(3), 1053–1064.
<https://doi.org/10.2353/ajpath.2010.100105>
- Li, W., Lee, M.-R., Kim, T., Kim, Y. W., & Cho, M.-Y. (2018). Activated STAT3 may participate in tumor progression through increasing CD133/survivin expression in early stage of colon cancer. *Biochemical and Biophysical Research Communications*, 497(1), 354–361.
<https://doi.org/10.1016/j.bbrc.2018.02.084>
- Li, Z. (2013). CD133: A stem cell biomarker and beyond. *Experimental Hematology and Oncology*, 2(1), 1. <https://doi.org/10.1186/2162-3619-2-17>
- Lim, D., & Oliva, E. (2013). Precursors and pathogenesis of ovarian carcinoma. *Pathology*, 45(3), 229–242. <https://doi.org/10.1097/PAT.0b013e32835f2264>
- Liou, G. Y. (2019). CD133 as a regulator of cancer metastasis through the cancer stem cells. *The International Journal of Biochemistry & Cell Biology*.
<https://www.sciencedirect.com/science/article/pii/S135727251830236X>
- Liu, Y., Ren, S., Xie, L., Cui, C., Xing, Y., Liu, C., Cao, B., Yang, F., Li, Y., Chen, X., Wei, Y., Lu, H., & Jiang, J. (2015). Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth. *Oncotarget*, 6(24), 20650–20660. <https://doi.org/10.18632/oncotarget.4115>
- Maeda, S., Shinchi, H., Kurahara, H., Matakai, Y., Maemura, K., Sato, M., Natsugoe, S., Aikou, T., & Takao, S. (2008). CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. *British Journal of ...*, March, 1389–1397.
<https://doi.org/10.1038/sj.bjc.6604307>
- Malpica, A., & Wong, K. K. (2016). The molecular pathology of ovarian serous borderline tumors. *Annals of Oncology*, 27(Supplement 1), i16–i19.
<https://doi.org/10.1093/annonc/mdw089>
- Mardani, A., Gheyanchi, E., Mousavie, S. H., Madjd, Z., & Shooshtarizadeh, T. (2020). Clinical Significance of Cancer Stem Cell Markers CD133 and CXCR4 in Osteosarcomas. *Asian Pacific Journal of Cancer Prevention*, 21, 67–73. <https://doi.org/10.31557/APJCP.2020.21.1.67>
- Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. J. (1991). Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*, 9(3), 389–393. <https://doi.org/10.1200/JCO.1991.9.3.389>
- Min, K. J., So, K. A., Ouh, Y. T., Hong, J. H., & Lee, J. K. (2012). The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers. In *Journal of ovarian research*. Springer.
<https://link.springer.com/article/10.1186/1757-2215-5-28>
- Mitra, A. K. (2016). Ovarian Cancer Metastasis: A Unique Mechanism of Dissemination. *Tumor Metastasis*. <https://doi.org/10.5772/64700>
- Motegi, H., Kamoshima, Y., Terasaka, S., Kobayashi, H., & Houkin, K. (2014).

- Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells. *Neuropathology*, 34(4), 378–385. <https://doi.org/10.1111/neup.12117>
- Nadal, R., Ortega, F. G., Salido, M., Lorente, J. A., Rodriguez-Rivera, M., Delgado-Rodriguez, M., Macia, M., Fernandez, A., Corominas, J. M., Garcia-Puche, J. L., Sanchez-Rovira, P., Sole, F., & Serrano, M. J. (2013). CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. *International Journal of Cancer*, 1–19. <https://doi.org/10.1002/acr.22212>
- Nomura, A., Banerjee, S., Chugh, R., Dudeja, V., Yamamoto, M., Vickers, S. M., & Saluja, A. K. (2015). CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. *Oncotarget*, 6(10), 8313–8322. <https://doi.org/10.18632/oncotarget.3228>
- Park, E. K., Lee, J. C., Park, J. W., Bang, S. Y., Yi, S. A., Kim, B. K., Park, J. H., Kwon, S. H., You, J. S., Nam, S. W., Cho, E. J., & Han, J. W. (2015). Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. *Cell Death and Disease*, 6, 1–12. <https://doi.org/10.1038/cddis.2015.313>
- Parte, S., Bhartiya, D., Telang, J., Daithankar, V., Salvi, V., Zaveri, K., & Hinduja, I. (2011). Detection, Characterization, and Spontaneous Differentiation In Vitro of Very Small Embryonic-Like Putative Stem Cells in Adult Mammalian Ovary. *Stem Cells and Development*, 20(8). <https://doi.org/10.1089/scd.2010.0461>
- Prat, J. (2012). Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features. *Virchows Archiv*, 460(3), 237–249. <https://doi.org/10.1007/s00428-012-1203-5>
- Rappa, G., Mercapide, J., Anzanello, F., Pope, R. M., & Lorico, A. (2013). Biochemical and biological characterization of exosomes containing prominin-1/CD133. *Molecular Cancer*, 12, 62. <https://doi.org/10.1186/1476-4598-12-62>
- Ren, F., Sheng, W., & Du, X. (2013). CD133 : A cancer stem cells marker , is used in colorectal cancers. *World Journal of Gastroenterology*, 19(17), 2603–2611. <https://doi.org/10.3748/wjg.v19.i17.2603>
- Roy, L., Bobbs, A., Sattler, R., Kurkewich, J. L., Dausinas, P. B., Nallathamby, P., & Dahl, K. D. C. (2018). CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche. *Cancer Growth and Metastasis*, 11, 1–11. <https://doi.org/10.1177/1179064418767882>
- Semenza, G. L. (2014). Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. *Annual Review of Pathology*, 9, 47–71. <https://doi.org/10.1146/annurev-pathol-012513-104720>
- Silva, I. A., Bai, S., McLean, K., Yang, K., Griffith, K., Thomas, D., Ginestier, C., Johnston, C., Kueck, A., Reynolds, R. K., Wicha, M. S., & Buckanovich, R. J. (2011). Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. *Cancer Research*, 71(11), 3991–4001. <https://doi.org/10.1158/0008-5472.CAN-10-3175>
- Skubitz, A. P. N., Taras, E. P., Boylan, K. L. M., Waldron, N. N., Oh, S., Panoskaltis-Mortari, A., & Vallera, D. A. (2013). Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. *Gynecologic Oncology*, 130(3), 579–587. <https://doi.org/10.1016/j.ygyno.2013.05.027>

- Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R. D., Engh, J., Iwama, T., Kunisada, T., Kassam, A. B., Pollack, I. F., & Park, D. M. (2009). Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 α . *Oncogene*, *28*(45), 3949–3959. <https://doi.org/10.1038/onc.2009.252>
- Soslow, R. A., Campbell, I., Malpica, A., Brenton, J. D., Vang, R., Davidson, B., Folkins, A. K., Kong, C. S., & Soerjomataram, I. (2020). High Grade Serous Carcinoma of the ovary. In *WHO Classification of Tumours Editorial Board. Female genital tumours*. International Agency for Research on Cancer. <https://tumourclassification.iarc.who.int/chaptercontent/34/13>
- Suprayitno, A. D., Fauziah, D., & Mastutik, G. (2021). Hubungan Ekspresi CD133 dan EGFR Terhadap Derajat Keganasan pada Karsinoma Ovarium
Correlation between CD133 and EGFR Expression with Grading of Ovarian Carcinoma. *Majalah Patologi Indonesia*, *30*(1), 211–218.
- Suster, Natasa Kenda, & Virant-Klun, I. (2019). Presence and role of stem cells in ovarian cancer. *World Journal of Stem Cells*, *11*(7), 383–397. <https://doi.org/10.4252/wjsc.v11.i7.383>
- Suster, Natasha Kenda, Smrkolj, S., & Virant-Klun, I. (2017). Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers. *J Ovarian Res*, *10*, 11.
- Taipale, J., & Beachy, P. A. (2001). The Hedgehog and Wnt signalling pathways in cancer. *Nature*, *411*.
- Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018). Ovarian cancer statistics, 2018. *CA Cancer J Clin*, *68*(4), 284–296. <https://doi.org/10.3322/caac.21456>
- Tsuchida, N., Murugan, A. K., & Grieco, M. (2016). Kirsten Ras* oncogene: significance of its discovery in human cancer research. *Oncotarget*, *7*(29), 46717–46733. <https://doi.org/10.18632/oncotarget.8773>
- Ullah, M. (2019). *CD133 Clinical Trials : Safety and Efficacy. November*. <https://doi.org/10.4172/2325-9620.1000151>
- Varas-Godoy, M., Rice, G., & Illanes, S. E. (2017). The Crosstalk between Ovarian Cancer Stem Cell Niche and the Tumor Microenvironment. *Stem Cells International*, *2017*. <https://doi.org/10.1155/2017/5263974>
- Vathipadiekal, V., Saxena, D., Mok, S. C., Hauschka, P. V., Ozbun, L., & Birrer, M. J. (2012). Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. *PLoS ONE*, *7*(1), 1–12. <https://doi.org/10.1371/journal.pone.0029079>
- Virant-klun, I., Skutella, T., Kubista, M., Vogler, A., Sinkovec, J., & Meden-vrtovec, H. (2013). Expression of Pluripotency and Oocyte-Related Genes in Single Putative Stem Cells from Human Adult Ovarian Surface Epithelium Cultured In Vitro in the Presence of Follicular Fluid. *BioMed Research International*, *2013*.
- Wei, Y., Jiang, Y., Zou, F., Liu, Y., Wang, S., Xu, N., Xu, W., & Cui, C. (2013). Activation of PI3K / Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. *PNAS*, *110*(17), 6829–6834. <https://doi.org/10.1073/pnas.1217002110>
- Won, C., Kim, B. H., Yi, E. H., Choi, K. J., Kim, E. K., Jeong, J. M., Lee, J. H., Jang, J. J., Yoon, J. H., Jeong, W. Il, Park, I. C., Kim, T. W., Bae, S. S.,

- Factor, V. M., Ma, S., Thorgeirsson, S. S., Lee, Y. H., & Ye, S. K. (2015). Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. *Hepatology*, *62*(4), 1160–1173. <https://doi.org/10.1002/hep.27968>
- Wong, K. K., Tsang, Y. T. M., Deavers, M. T., Mok, S. C., Zu, Z., Sun, C., Malpica, A., Wolf, J. K., Lu, K. H., & Gershenson, D. M. (2010). BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. *American Journal of Pathology*, *177*(4), 1611–1617. <https://doi.org/10.2353/ajpath.2010.100212>
- Wu, Y., & Wu, P. Y. (2009). CD133 as a Marker for Cancer Stem Cells : Progresses and Concerns. *Stem Cells and Development*, *18*(8). <https://doi.org/10.1089/scd.2008.0338>
- Yin, A. H., Miraglia, S., Zanjani, E. D., Almeida-Porada, G., Ogawa, M., Leary, A. G., Olweus, J., Kearney, J., & Buck, D. W. (1997). AC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells. *Blood*, *90*(12), 5002–5012. <https://doi.org/10.1182/blood.v90.12.5002>
- You, H., Ding, W., & Rountree, C. B. (2010). Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. *Hepatology (Baltimore, Md.)*, *51*(5), 1635–1644. <https://doi.org/10.1002/hep.23544>
- Zhang, J., Guo, X., Chang, D. Y., Rosen, D. G., Mercado-Urbe, I., & Liu, J. (2012). CD133 expression associated with poor prognosis in ovarian cancer. *Modern Pathology*, *25*(3), 456–464. <https://doi.org/10.1038/modpathol.2011.170>
- Zhang, L., Li, H., Ge, C., Li, M., Zhao, F. yu, Hou, H. lei, Zhu, M. xin, Tian, H., Zhang, L. xing, Chen, T. yang, Jiang, G. ping, Xie, H. yang, Cui, Y., Yao, M., & Li, J. jun. (2014). Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma. *Oncotarget*, *5*(21), 10621–10635. <https://doi.org/10.18632/oncotarget.2524>
- Zhang, S., Balch, C., Chan, M. W., Lai, H., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H., & Nephew, K. P. (2008). Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors. *Cancer Research*, *68*(11), 4311–4320. <https://doi.org/10.1158/0008-5472.CAN-08-0364>. Identification
- Zhou, Q., Chen, A., Song, H., Tao, J., & Yang, H. (2015). Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis. *Int J Clin Exp Med*, *8*(3), 3080–3088.
- Zong, X., & Nephew, K. P. (2019). Ovarian cancer stem cells: Role in metastasis and opportunity for therapeutic targeting. *Cancers*, *11*(7), 1–22. <https://doi.org/10.3390/cancers11070934>

LAMPIRAN


Lampiran 1: Dokumentasi Penelitian



Pemotongan Blok Parafin Sampel Jaringan



Deparafinisasi, Rehidrasi



Imunostaining



Mounting

ran 2: Tabulasi Data


TABULASI DATA						IHC CD133			
Code Sampel	Usia	Diagnosa	Kode Diagnosa	LVI	Metastasis	Intensitas	Persentase	Ekspresi	H-Score
7777	41	LGSC	0	0	0	3	3	2	9
7072	43	HGSC	1	1	0	3	60	2	180
4888	50	HGSC	1	1	0	0	0	1	0
5588	66	LGSC	0	0	0	0	0	1	0
5420	55	LGSC	0	0	0	3	2	2	6
3132	36	LGSC	0	1	1	2	80	2	160
3201	66	LGSC	0	0	1	2	80	2	160
9520	56	LGSC	0	1	1	2	80	2	160
0056	36	LGSC	0	1	1	3	5	2	15
58391A	59	HGSC	1	0	0	3	60	2	180
5384B	51	HGSC	1	1	1	3	30	2	90
1909H	50	HGSC	1	0	0	3	40	2	120
22851A	54	HGSC	1	0	0	1	5	2	5
2831A	58	LGSC	0	0	0	1	2	2	2
3545C	56	HGSC	1	1	1	3	80	2	240
4045A	49	HGSC	1	1	1	1	30	2	30
4142B	31	HGSC	1	0	0	3	3	2	9
42331B	71	HGSC	1	1	1	1	30	2	30
4394A	28	LGSC	0	0	0	3	10	2	30
5093A	54	HGSC	1	0	1	1	5	2	5

5190D	63	HGSC	1	1	1	3	40	2	120
5251ID	56	HGSC	1	1	1	3	60	2	180
UH.17.1173B	60	HGSC	1	1	1	0	0	1	0
UH.17.519IA	24	HGSC	1	0	0	0	0	1	0
UH.18.0709A	44	LGSC	0	0	1	0	0	1	0
UH.18.0727B	44	HGSC	1	1	1	1	6	1	6
UH.18.0895C	48	HGSC	1	0	0	3	7	2	21
UH.18.1030A	45	HGSC	1	0	0	1	4	2	4
UH.18.1057A	35	LGSC	0	0	0	1	7	2	7
UH.18.1074IIC	49	HGSC	1	1	1	3	30	2	90
UH.18.1081F	45	HGSC	1	1	1	3	60	2	180
UH.18.1105IA	33	HGSC	1	1	0	2	40	2	80
UH.18.1259A	34	HGSC	1	1	0	1	1	1	1
UH.18.768A	42	HGSC	1	1	1	2	30	2	60
UH.19.0530	38	LGSC	0	0	0	3	10	2	30
UH.19.1334A	60	HGSC	1	1	1	3	50	2	150
UH.19.1447A	50	HGSC	1	1	1	1	5	2	5
UH.19.848A	45	HGSC	1	0	0	3	30	2	90
UH.20.140A	39	HGSC	1	1	0	1	3	2	3
UH.20.411C	59	HGSC	1	0	0	1	2	2	2
UH.20.636A	61	LGSC	0	0	0	0	0	1	0
UH.21.009	52	HGSC	1	0	0	3	70	2	210
UH.21.334	48	LGSC	0	1	1	2	8	2	16
18.0365	50	HGSC	1	0	1	1	10	2	10
18.0652	65	HGSC	1	0	0	3	7	2	21


18.0844	53	HGSC	1	1	1	1	8	1	8
18.0950	58	HGSC	1	1	0	3	8	2	24
18.1810	51	HGSC	1	1	1	2	30	2	60
18.1917	52	LGSC	0	1	1	1	3	2	3
18.2134	49	LGSC	0	0	0	3	30	2	90
18.2271	47	LGSC	0	1	1	0	0	1	0
18.2443	54	LGSC	0	0	0	1	6	2	6
18.2475	51	HGSC	1	0	0	2	4	2	8
18.2606	49	LGSC	0	1	1	1	5	2	5
18.3327	40	HGSC	1	1	1	2	5	1	10
18.3428	37	LGSC	0	0	1	1	3	2	3
18.4311	57	LGSC	0	0	0	1	9	2	9
18.4311	57	LGSC	0	0	0	3	3	2	9
19.0103	66	HGSC	1	0	0	3	3	2	9
19.0430	47	HGSC	1	0	1	3	8	2	24
19.0971	50	HGSC	1	1	1	1	30	2	30
19.1571	20	LGSC	0	0	0	1	20	2	20
19.1746	47	HGSC	1	0	1	2	5	2	10
19.1904	49	HGSC	1	1	1	3	30	2	90
19.1994	61	HGSC	1	0	0	0	0	1	0
19.2042	55	HGSC	1	1	0	3	2	2	6
19.2137	43	HGSC	1	1	1	3	80	2	240
19.2163	66	LGSC	0	0	0	3	5	2	15
19.2774	45	HGSC	1	1	1	3	80	2	240
19.2937	62	HGSC	1	1	1	3	30	2	90

19.3012	54	HGSC	1	1	1	3	50	2	150
19.3464	49	HGSC	1	0	1	3	40	2	120
19.4821	34	HGSC	1	1	1	3	20	2	60
20.0516	49	HGSC	1	0	0	2	4	2	8
20.0558	46	HGSC	1	1	1	2	25	1	50
20.0670	46	HGSC	1	0	0	1	40	2	40
20.0702	64	HGSC	1	1	1	3	5	2	15
20.0849	68	HGSC	1	0	0	1	10	2	10
20.1420	77	HGSC	1	1	0	1	3	2	3
20.1683	23	LGSC	0	1	1	3	9	2	27
20.2153	46	LGSC	0	0	0	0	0	1	0
20.2463	42	HGSC	1	0	0	3	20	2	60
20.2581	48	LGSC	0	0	0	2	20	2	40
21.0091	47	LGSC	0	1	1	3	70	2	210
21.0739	55	LGSC	0	1	1	2	60	2	120
21.1152	63	LGSC	0	1	1	1	70	2	70
21.1166	43	LGSC	0	1	1	2	30	2	60
21.1466	55	HGSC	1	0	0	2	30	2	60
UH.18.387-2A	31	HGSC	1	1	1	3	5	2	15
20.2550	44	LGSC	0	0	0	0	0	1	0
21.547	54	LGSC	0	1	1	3	80	2	240

Lampiran 3: Persetujuan Etik





KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 309/UN4.6.4.5.31/ PP36/ 2021 Tanggal: 3 Mei 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21040265	No Sponsor	
Peneliti Utama	dr. Dzul Ikram	Protokol	
Judul Peneliti	Profil Ekspresi Cancer Stem Cells CD133 pada Karsinoma Ovarium Tipe Serosum		
No Versi Protokol	1	Tanggal Versi	24 April 2021
No Versi PSP		Tanggal Versi	
Tempat Penelitian	Laboratorium Patologi Anatomi RS Universitas Hasanuddin Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted	Masa Berlaku 3 Mei 2021 sampai 3 Mei 2022	Frekuensi review lanjutan
	<input type="checkbox"/> Expedited		
	<input type="checkbox"/> Fullboard Tanggal		
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan